This vax's success hinges on trust

Cervical cancer is the second most common cancer among Indian women, causing over 42,000 deaths annually. Against this backdrop, GoI's decision to introduce a single-dose human papillomavirus (HPV) vaccine - beginning its 90-day rollout today and targeting 14-yr-old girls - marks a long-overdue public health intervention. Yet, even before implementation, the vaccine has encountered resistance, reflecting a broader pattern of scepticism that has accompanied HPV immunisation efforts worldwide.

Proponents argue the case is compelling. WHO and leading oncologists consistently endorse it as one of the most effective tools for cancer prevention. However, concerns about long-term safety data, the pharma sector's influence on policy decisions, and the robustness of post-vaccination monitoring have fuelled distrust among some parents and health advocates. Past controversies - including a 2009 clinical trial in India suspended over ethical concerns - continue to cast a shadow over public perception. Japan suspended proactive recommendations following reports of adverse effects, while parts of Europe and Africa have witnessed similar waves of hesitancy.

The decision to make the vaccine voluntary rather than mandatory adds another layer of complexity. In the event of adverse outcomes, the state's liability may be limited, as seen during Covid litigation when GoI informed the Supreme Court that vaccination was not binding, complicating claims around informed consent. Ultimately, the success of the HPV vaccination drive will depend less on policy design and more on the state's ability to build public trust through sustained and transparent communication and rigorous safety monitoring - especially in rural areas where health literacy remains uneven.